Stryker Co. (NYSE:SYK) Position Lessened by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC reduced its stake in shares of Stryker Co. (NYSE:SYK) by 7.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,576 shares of the medical technology company’s stock after selling 210 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Stryker were worth $931,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Centennial Bank AR increased its position in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Stryker in the third quarter worth $36,000. Hara Capital LLC acquired a new position in shares of Stryker during the third quarter valued at $42,000. HBW Advisory Services LLC bought a new stake in shares of Stryker during the third quarter valued at about $42,000. Finally, Grove Bank & Trust lifted its holdings in Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.1 %

Stryker stock opened at $384.63 on Tuesday. Stryker Co. has a 52 week low of $285.79 and a 52 week high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market capitalization of $146.63 billion, a price-to-earnings ratio of 41.23, a P/E/G ratio of 2.90 and a beta of 0.91. The company has a 50 day moving average price of $366.45 and a 200 day moving average price of $350.00.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter last year, the firm posted $2.46 earnings per share. Stryker’s revenue was up 11.9% compared to the same quarter last year. Research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on SYK shares. Canaccord Genuity Group boosted their price target on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC boosted their target price on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Stifel Nicolaus decreased their price target on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. BTIG Research boosted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird upped their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at $3,685,213.16. This represents a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,781 shares of company stock worth $24,612,275 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.